Insights

Acquisition Activity ArQule has undergone multiple high-profile acquisitions including Merck's $2.7 billion purchase and prior deals with Peloton Therapeutics and Tilos Therapeutics, indicating a strong industry interest in their targeted cancer therapies and potential for partnership or licensing opportunities.

Innovative Pipeline The company’s development of new drugs like ARQ 531, currently in clinical trials for B-cell malignancies, presents an opportunity to engage with biotech firms or research institutions looking for innovative treatment options in oncology.

Strategic Focus ArQule’s emphasis on precision medicine with proprietary kinase libraries and biomarker-guided trials aligns with the growing market demand for personalized therapies, making it a prime target for companies offering complementary diagnostic or research tools.

Research and Development With a focused R&D strategy and multiple drugs in clinical development, ArQule could benefit from partnerships in clinical research, contract manufacturing, or regulatory consulting to accelerate drug development and commercialization.

Market Positioning Operating in the competitive biotech sector with recent transactions signaling high valuation, ArQule presents opportunities for firms specializing in biotech investment, licensing, or collaboration to leverage their innovative oncology pipeline and pipeline management expertise.

ArQule Tech Stack

ArQule uses 8 technology products and services including MySQL, Swiftype, Font Awesome, and more. Explore ArQule's tech stack below.

  • MySQL
    Database
  • Swiftype
    Enterprise Search
  • Font Awesome
    Font Scripts
  • Google Charts
    Javascript Graphics
  • Modernizr
    Javascript Libraries
  • WP Engine
    Platform As A Service
  • Google Analytics
    Web Analytics
  • Nginx
    Web Servers

Media & News

ArQule's Email Address Formats

ArQule uses at least 1 format(s):
ArQule Email FormatsExamplePercentage
FLast@arqule.comJDoe@arqule.com
91%
LFirst@arqule.comDJohn@arqule.com
4%
First.Last@arqule.comJohn.Doe@arqule.com
3%
FirstLast@arqule.comJohnDoe@arqule.com
2%

Frequently Asked Questions

What is ArQule's phone number?

Minus sign iconPlus sign icon
You can contact ArQule's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is ArQule's stock symbol?

Minus sign iconPlus sign icon
ArQule is a publicly traded company; the company's stock symbol is ARQL.

What is ArQule's official website and social media links?

Minus sign iconPlus sign icon
ArQule's official website is arqule.com and has social profiles on LinkedIn.

What is ArQule's SIC code NAICS code?

Minus sign iconPlus sign icon
ArQule's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ArQule have currently?

Minus sign iconPlus sign icon
As of December 2025, ArQule has approximately 79 employees across 3 continents, including North AmericaEuropeSouth America. Key team members include Chief Executive Officer: P. P.Vice President And Chief Corporate Counsel: R. J. C.Vice President Of Professional Services North America: M. B.. Explore ArQule's employee directory with LeadIQ.

What industry does ArQule belong to?

Minus sign iconPlus sign icon
ArQule operates in the Biotechnology Research industry.

What technology does ArQule use?

Minus sign iconPlus sign icon
ArQule's tech stack includes MySQLSwiftypeFont AwesomeGoogle ChartsModernizrWP EngineGoogle AnalyticsNginx.

What is ArQule's email format?

Minus sign iconPlus sign icon
ArQule's email format typically follows the pattern of FLast@arqule.com. Find more ArQule email formats with LeadIQ.

ArQule

Biotechnology ResearchMassachusetts, United States51-200 Employees

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and certain rare diseases.

Our mission is to discover, develop and commercialize novel small molecule drugs that will dramatically extend and improve the lives of patients in areas of high unmet need.

With four internally discovered drugs in multiple biomarker guided clinical trials and an enriched proprietary kinase library from which to select additional drug candidates, ArQule is delivering on the potential of precision medicine by providing its patients with novel therapies for multiple hard to treat indications and its shareholders with a focused, highly efficient and cost effective research and development strategy.

ArQule is led by a senior management team with significant clinical and commercial expertise that provides the leadership required to optimize its opportunities for success in a rapidly changing and highly competitive field.

Section iconCompany Overview

Phone number
Website
arqule.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ARQL
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
51-200

Section iconFunding & Financials

  • $10M$25M

    ArQule's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $10M$25M

    ArQule's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.